Intellia Therapeutics (NASDAQ:NTLA) Hits New 12-Month Low - What's Next?

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) reached a new 52-week low during trading on Wednesday . The company traded as low as $14.37 and last traded at $14.71, with a volume of 374725 shares changing hands. The stock had previously closed at $14.99.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. The Goldman Sachs Group reduced their price target on shares of Intellia Therapeutics from $31.00 to $20.00 and set a "neutral" rating for the company in a report on Friday, October 25th. Citigroup lowered their target price on Intellia Therapeutics from $25.00 to $19.00 and set a "neutral" rating for the company in a report on Friday, October 25th. Evercore ISI upgraded Intellia Therapeutics to a "strong-buy" rating in a report on Friday, August 9th. Royal Bank of Canada restated an "outperform" rating and set a $54.00 price objective on shares of Intellia Therapeutics in a research note on Thursday, September 19th. Finally, JPMorgan Chase & Co. dropped their price objective on Intellia Therapeutics from $61.00 to $55.00 and set an "overweight" rating on the stock in a research report on Monday, August 12th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Intellia Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $59.13.

Intellia Therapeutics Price Performance

The firm has a market cap of $1.46 billion, a PE ratio of -2.74 and a beta of 1.76. The stock's fifty day simple moving average is $20.40 and its 200-day simple moving average is $22.59.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.29). The company had revenue of $7.00 million during the quarter, compared to the consensus estimate of $19.68 million. Intellia Therapeutics's revenue was down 48.5% compared to the same quarter last year. During the same period last year, the business earned ($1.40) EPS. Analysts expect that Intellia Therapeutics, Inc. will post -5.22 earnings per share for the current year.

Insider Activity at Intellia Therapeutics

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,012 shares of the firm's stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the completion of the transaction, the chief accounting officer now directly owns 47,012 shares of the company's stock, valued at approximately $893,698.12. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 3.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Intellia Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Blue Trust Inc. lifted its holdings in shares of Intellia Therapeutics by 1,664.3% in the 2nd quarter. Blue Trust Inc. now owns 1,482 shares of the company's stock valued at $33,000 after buying an additional 1,398 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in Intellia Therapeutics by 763.5% in the second quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company's stock valued at $39,000 after acquiring an additional 1,550 shares during the period. Eastern Bank acquired a new stake in shares of Intellia Therapeutics during the 3rd quarter worth approximately $41,000. Values First Advisors Inc. purchased a new position in shares of Intellia Therapeutics during the 3rd quarter valued at approximately $54,000. Finally, First Horizon Advisors Inc. increased its holdings in shares of Intellia Therapeutics by 22.1% during the 2nd quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company's stock valued at $58,000 after purchasing an additional 472 shares in the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.